STAT

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

Novartis' contract with Michael Cohen, President Trump's lawyer, isn't its first questionable deal.
Source: Photo illustration: Dom Smith/STAT; Photo: Mark Wilson/Getty Images

When Donald Trump’s lawyer, Michael Cohen, approached Novartis early last year to provide access to the new Trump administration, the company’s response was tone-deaf. But it was hardly a surprise.

The personal lawyer and “fixer” for the president came knocking as big drug makers were anxious about the future, since candidate Trump had for through-the-roof prices. So former Novartis chief executive Joe Jimenez quickly authorized a one-year, . This was considerably more than Novartis Washington lobbyists. And it wasn’t for Cohen’s policy expertise — he knew nothing about health care.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.

Related Books & Audiobooks